Evidence map›Paper›PMID 38937827›Full record

ArticleJournal of ovarian research2024

Genomic alteration discordance in the paired primary-recurrent ovarian cancers: based on the comprehensive genomic profiling (CGP) analysis.

Jiayin Dong, Jing Ni, Jiahui Chen, Xuening Wang, Luxin Ye, Xia Xu, Wenwen Guo, Xiaoxiang Chen

Abstract read
In one paragraph

Article in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiayin Dong *Department of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 42 # Baiziting street, Nanjing, Jiangsu, 210009, People's Republic of China.
Jing Ni *Department of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 42 # Baiziting street, Nanjing, Jiangsu, 210009, People's Republic of China.
Jiahui ChenDepartment of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 42 # Baiziting street, Nanjing, Jiangsu, 210009, People's Republic of China.
Xuening WangDepartment of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 42 # Baiziting street, Nanjing, Jiangsu, 210009, People's Republic of China.
Luxin YeDepartment of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 42 # Baiziting street, Nanjing, Jiangsu, 210009, People's Republic of China.
Xia XuDepartment of Chemotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 42 # Baiziting street, Nanjing, Jiangsu, 210009, People's Republic of China.
Wenwen GuoDepartment of Pathology, The Second Affiliated Hospital of Nanjing Medical University, 121 # Jiangjiayuan road, Nanjing, Jiangsu, 210011, People's Republic of China. hguowen@163.com.
Xiaoxiang ChenDepartment of Gynecologic Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 42 # Baiziting street, Nanjing, Jiangsu, 210009, People's Republic of China. cxxxxcyd@gmail.com.

Funding

789 Outstanding Talent Program of the Second Affiliated Hospital of Nanjing Medical University 789ZYRC202080122Jiangsu Provincial Scientific Research and Health Project ZD2022005Jiangsu Provincial Scientific Research and Health Project for Women and Children F202004National Natural Science Foundation of China 82302974Natural Science Foundation of Youth Fund Projects of Jiangsu Province BK20210976
6 · The paper itself

Abstract

purposeOvarian cancer (OC) is characterized by a high recurrence rate, and homologous recombination deficiency (HRD) is an important biomarker in the clinical management of OC. We investigated the differences in clinical genomic profiles between the primary and platinum-sensitive recurrent OC (PSROC), focusing on HRD status. MATERIALS AND

methodsA total of 40 formalin-fixed paraffin-embedded (FFPE) tissues of primary tumors and their first platinum-sensitive recurrence from 20 OC patients were collected, and comprehensive genomic profiling (CGP) analysis of FoundationOne

resultsBy comparing between paired samples, we found that genomic loss of heterozygosity (gLOH) score had a high intra-patient correlation (r

conclusionThe high genetic concordance of the short variants remains stable along OC recurrence. However, the results reveal significantly higher gLOH scores in the recurrent setting than in paired primaries, supporting further clinically instantaneity HRD assay strategy.

Indexed as

GenomicsNeoplasm Recurrence, LocalOvarian NeoplasmsAdultAgedBiomarkers, TumorFemaleGene Expression ProfilingHumansLoss of HeterozygosityMiddle AgedMutationBiomarkers, TumorComprehensive genomic profiling (CGP)Genomic loss of heterozygosity (gLOH)Homologous recombination deficiency (HRD)Ovarian cancer

Identifiers

PMID38937827
PMCPMC11212203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.